Roche, already partnered with Poseida Therapeutics in the development of off-the-shelf cell therapies for blood cancers, is broadening its ambitions with the modality through a deal to acquire the ...
Roche Holding AG's acquisition of Poseida for $1.5bn is a smart move by Big Pharma as allogeneic cell therapies are becoming increasingly de-risked. Despite recent challenges, Roche's diverse ...
On Tuesday, Roche Holdings AG (OTC:RHHBY) agreed to acquire Poseida Therapeutics, Inc. (NASDAQ:PSTX) for an equity value of approximately $1.5 billion on a fully diluted basis. The deal consideration ...
Roche has struck a $1.5 billion deal to buy Poseida Therapeutics. The takeover will establish off-the-shelf cell therapies, which Roche has said can democratize CAR-Ts, as a new core capability at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results